SPAC Feed’s Post

A really useful article from my colleagues Jonathan GREENWOOD and Katharine Robinson Although it's framed in the biotech space, I think the useful tips in this post apply for any business owners contemplating an exit. So if that's you - it's definitely worth a read. #MergersAndAcquisitions #PrivateEquity #DealMaking #BusinessOwner #Entrepreneurs

Blank-check company Vision Sensing Acquisition Corp. (NASDAQ: VSAC) Announces Definitive Agreement and Plan of Merger with Mediforum Co., Ltd, a leading Korean biotechnology company. Mediforum will have a pre-money enterprise value of US$250 million at closing, and is also looking to secure additional financing in an amount up to US$50 million from private placement of equity, debt or other alternative financing. Norwich Capital Limited acts as the Lead Advisor for Mediforum. “Facilitating and coordinating this collaboration among the parties was no small feat. Despite the challenges posed by experiential differences and diverse origins, our collective commitment and strategic vision have triumphed. I commend the dedicated efforts of all parties involved”, said Jason Wong Kon Man, our Founder and CEO. Source: https://lnkd.in/diETDnsE #norwichhk #norwich #norwichcapital #spac #despac #ipo #nasdaq #nasdaqlisted #nyse #stockmarket #capitalmarkets #privateequity #fundraising #fundraiser #funding #invest #investing #investments

On today’s #BiotechHangout Daphne Zohar Josh Schimmer Tim Opler Chris Garabedian & Grace Colón cover the IPO market including $AUTL, $SANA, $MLYS, $TNYA & $KYTX ’s upsized IPO, $NVS to acquire $MOR for $2.9B, $GILD walks away from Tizona deal, data from $LLY, $AMGN, $FDMT, $JNJ & $VRTX, plus $GILD & $LLY drug discontinuations, Novo Holdings to acquire $CTLT in $16.5B deal, @US_FDA AI for drug surveillance, Scion Life Sciences launches w/$310M fund, & more:  https://lnkd.in/eDUukchv

French biotech: disappointing post-IPO performance. Over the period between January 2012 and February 2024, the analysis of the performance of French biotechs is disastrous, with only Medincell having a share price higher than that of its IPO. There are many reasons for this, with many clinical and regulatory failures confirming the binary nature of this industry. The problem is that the likelihood of seeing the light at the end of the tunnel is low for many companies. Is the peak negative sentiment is behind or ahead of us?

Our 2023 Activity Report is out! 🔗 https://lnkd.in/eBbY-Zbm 📈 In this report we provide a comprehensive market analysis of 2023 with key themes and outlooks for 2024 within our core sectors in Healthcare, Software & Fintech, Energy Transition & Sustainability, Industrial Tech, Business & Tech-enabled Services and NextGen Consumer. 🎯 2023 was a record year for Bryan Garnier. Notable transactions included CARBIOS’ €141m rights issue, the largest capital increase with public offer on Euronext Growth since 2015; the first combined offering of SEK 462m for a Swedish listed company with Egetis Therapeutics AB; the $236m Nasdaq IPO for Abivax marking the largest French Biotech; as well as the €875m tender offer for Boiron France. Get in touch to learn more. #ActivityReport2023 #ECM #PrivatePlacements #LBO #MergersAndAcquisitions  #GrowthCapital #Research #InvestmentOpportunities #Records #MergersAndAcquisitions

We are honoured to be featured in Bryan, Garnier & Co's 2023 Activity Report. Thank you for recognising our commitment to advancing gender equality in the world of mergers and acquisitions. Pretraga Partners is dedicated to promoting inclusivity and diversity within the Investment Banking and Private Equity. Let’s continue working towards a more inclusive future! #DiversityInFinance #GenderEquality #GenderDiversity #PrivateEquity #MergersAndAcquisitions #InvestmentOpportunities #ExecutiveSearch #InvestmentBanking #InvestmentBanker #PrivateEquityFirms #privateequity #PrivateEquityFirm #PrivateEquityLife #Finance #FinancialIndustry

Our Q2 2024 Market Conditions Report highlights how there has been a substantial improvement in both the private and public biotech capital markets in H1 2024, with total deal value surpassing the total value for the entire year of 2023. However, the public markets remain challenging for earlier stage companies, and the IPO window remains largely closed, favoring later-stage companies with robust data and insider support. Download Locust Walk’s Q2 2024 Market Conditions Report to learn more about the biopharma landscapes: https://lnkd.in/eZuFcVpG

UK Biotech IPO An IPO in the U.S. market may look very appealing to your U.K. biotech company, but what about the procedural barriers that make the process challenging? Our experts have experience with this complex process and have put together a step by step guide. Please reach out to us if you would like to hear how CFGI can support you on your IPO journey. Read our eBook to see how it works: https://bit.ly/450kZHp #CFGI #UK #IPO #Biotech #GoingPublic

Newcourt Acquisition in a proxy filing called a Jan. 18 meetign for shareholders to vote on the proposed business combination with Psyence Bioscience. The deal values Psyence Biomedical at a pre-money equity value of $50 million.  A subsidiary of Psyence Group, the Toronto-based target is a clinical-stage life science biotechnology company developing uses for nature-derived psilocybin in mental health and wellbeing. At deal announcement a year ago, terms called for Psyence to receive a minimum of $20 million cash held in trust. Newcourt raised $220 million in an October 2021 IPO, although the account is now down to approximately $12.8 million as of Jan. 9, according to the proxy. Currently, the Newcourt sponsor owns approximately 84.8% of the SPAC’s outstanding shares.  https://lnkd.in/d_fEGTRH

🚨The Most-Read M&A Deal Today: Jefferies and Goldman Sachs Confirm Advisory on GTCR LLC’s $627M Surmodics, Inc. Acquisition - Deal Summary Krugman Insights offers Reliable and Comprehensive Insights across M&A, Investment Banking, Private Equity, and Asset Management. 🔎 Financial Advisors on the Deal: Jefferies, Goldman Sachs 🔎 Legal Advisors on the Deal: Faegre Drinker, Kirkland & Ellis, Cleary Gottlieb Steen & Hamilton LLP 🔎 Key Stakeholders: GTCR LLC (Acquirer), Surmodics, Inc.. (Target) 💡 GTCR is set to acquire Surmodics, a leader in surface modification technologies for medical devices and in vitro diagnostics, for $627 million. Surmodics’ shareholders will receive $43 per share, a 41.1% premium over the 30-day average closing price. This acquisition promises immediate value for shareholders and positions Surmodics for future growth under GTCR's expertise. The transaction is expected to close in the second half of 2024, pending customary conditions, including shareholder and regulatory approvals. Post-acquisition, Surmodics will become a privately held company and delist from Nasdaq. ✅ TRY 30 DAYS FREE: https://lnkd.in/eBHYx37M ✅ FULL ARTICLE HERE: https://lnkd.in/eeu2GV5q #Jefferies #GoldmanSachs #GTCR #Surmodics #MergersAndAcquisitions #InvestmentBanking #CorporateFinance #HealthcareSector #StrategicPartnership #GlobalGrowth #FinancialAdvisory